1. PBP4 is required for serum-induced cell wall thickening and antibiotic tolerance in Staphylococcus aureus .
- Author
-
Ledger EVK and Massey RC
- Subjects
- Peptidoglycan metabolism, Humans, Staphylococcal Infections microbiology, Staphylococcal Infections drug therapy, Cefoxitin pharmacology, Bacterial Proteins genetics, Bacterial Proteins metabolism, Methicillin-Resistant Staphylococcus aureus drug effects, Methicillin-Resistant Staphylococcus aureus genetics, Mutation, Serum, Cell Wall drug effects, Cell Wall metabolism, Penicillin-Binding Proteins genetics, Penicillin-Binding Proteins metabolism, Anti-Bacterial Agents pharmacology, Staphylococcus aureus drug effects, Staphylococcus aureus genetics, Daptomycin pharmacology, Microbial Sensitivity Tests
- Abstract
The bacterial pathogen Staphylococcus aureus responds to the host environment by synthesizing a thick peptidoglycan cell wall, which protects the bacterium from membrane-targeting antimicrobials and the immune response. However, the proteins required for this response were previously unknown. Here, we demonstrate by three independent approaches that the penicillin-binding protein PBP4 is crucial for serum-induced cell wall thickening. First, mutants lacking various non-essential cell wall synthesis enzymes were tested, revealing that a mutant lacking pbp4 was unable to generate a thick cell wall in serum. This resulted in reduced serum-induced tolerance of the pbp4 mutant toward the last resort antibiotic daptomycin relative to wild-type cells. Second, we found that serum-induced cell wall thickening occurred in each of a panel of 134 clinical bacteremia isolates, except for one strain with a naturally occurring mutation that results in an S140R substitution in the active site of PBP4. Finally, inhibition of PBP4 with cefoxitin prevented serum-induced cell wall thickening and the resulting antibiotic tolerance in the USA300 strain and clinical MRSA isolates. Together, this provides a rationale for combining daptomycin with cefoxitin, a PBP4 inhibitor, to potentially improve treatment outcomes for patients with invasive MRSA infections., Competing Interests: The authors declare no conflict of interest.
- Published
- 2024
- Full Text
- View/download PDF